Liver Enzyme Elevation After 177Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer.
J Nucl Med
; 62(7): 1016-1019, 2021 07 01.
Article
em En
| MEDLINE
| ID: mdl-33990402
ABSTRACT
177Lu-PSMA radioligand therapy is a promising new option for patients with metastasized castration-resistant prostate cancer, and the spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a patient with M1c disease (metastasis to the mediastinum, lungs, bones, and liver) who presented with elevated liver enzyme levels after receiving 177Lu-PSMA radioligand therapy for castration-resistant prostate cancer. Pretreatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Próstata Resistentes à Castração
/
Isótopos de Gálio
/
Radioisótopos de Gálio
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Nucl Med
Ano de publicação:
2021
Tipo de documento:
Article